Humacyte, Inc. (HUMA)
NASDAQ: HUMA · IEX Real-Time Price · USD
3.990
+0.090 (2.31%)
At close: Apr 26, 2024, 4:00 PM
4.000
+0.010 (0.25%)
After-hours: Apr 26, 2024, 7:37 PM EDT
Humacyte Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
183
Market Cap
475.15M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | 1.49M | -4.70M | -75.90% |
| Dec 31, 2019 | 6.19M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Community Health Systems | 12.52B |
| PetIQ | 1.10B |
| Avid Bioservices | 136.74M |
| Alector | 97.06M |
| UroGen Pharma | 82.71M |
| IGM Biosciences | 2.13M |
| Shattuck Labs | 1.66M |
HUMA News
- 8 days ago - Here's why the Humacyte (HUMA) stock price is pumping - Invezz
- 4 weeks ago - Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024 - GlobeNewsWire
- 5 weeks ago - Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update - GlobeNewsWire
- 5 weeks ago - Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024 - GlobeNewsWire
- 2 months ago - Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Humacyte, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma - GlobeNewsWire